Skip to main content

Market Overview

Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says

Share:
Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says

Emergent BioSolutions Inc (NYSE: EBS) has built the capacity to produce vaccines from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) around the clock, said CEO Bob Kramer on CNBC.

  • “We are operating at a level where our capacity is well in excess of 1 billion doses annually for those products.” said the CEO.
  • The company bagged a five-year deal with JNJ to produce its COVID-19 vaccine, valued at about $480 million for the first two years.
  • It also entered into a multi-year contract production pact for AstraZeneca’s COVID-19 vaccine. The three-year contract is valued at $174 million through 2021.
  • AZN contract is in addition to an $87 million deal that was announced to secure production space.
  • The J&J vaccine is being produced at Emergent BioSolutions’ Baltimore Bayview facility, one of three Centers for Innovation in Advanced Development and Manufacturing designated by the U.S. government as a rapid vaccine therapeutics manufacturing site.
  • In addition to Emergent BioSolutions, the White House earlier this week arranged a deal with Merck & Co Inc (NYSE: MRK) to help boost J&J’s one-dose vaccine production.
  • President Joe Biden said that he expects the U.S. to have a vaccine supply of 300 million within the next few months, which he says is substantial enough to reach all adults.
  • The projected timeline for building up this supply was also moved to May from the end of July.
  • J&J expects to deliver 20 million shots in the U.S. this month, while a total of 100 million doses are planned for the first half of this year.
  • Price Action: EBS shares closed 4.6% lower at $94.73 on Wednesday.
 

Related Articles (EBS + MRK)

View Comments and Join the Discussion!

Posted-In: CNBC COVID-19 VaccineBiotech News Health Care Contracts General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com